Immunotech Laboratories BG, 46 Tulch str, Sofia (2026)

We are a corporation, which is dedicated to the development of medicine for HIV-1 Infection, Chronic Infection, Hepatitis(A,B,C), Rheumatoid Arthritis, some types of Cancer and every disease, which can be treated by an improved immune system.

24/04/2024

To the Shareholders of Immunotech Laboratories Inc (IMMB) and the Partners of Immunotech Laboratories BG

Dear shareholders,
The medicinal products on the basis of the IPF platform – ITV-1, ITV-2, ITV-3, ITV-4, ITV-5 with US Patents № 7,479,538, № 7,625,565, № 8,066,982, № 8,067,531, № 8,309,072 and the exclusive rights over the production and distribution with a notary signed in the US agreement are the property of Immunotech Laboratories BG until 2030. Every reference to these patents and the clinical trial of ITV-1 by Enzolytics Inc, as well as other entities, is a breach of the exclusive rights of Immunotech Laboratories BG, which is illegal and punishable by law. We have informed the former and current management of Enzolytics, namely Charles Cotropia, Harry Zhabilov, Luchezar Ivanov that any reference to these patents on their side is illegal and made with the goal of misleading shareholders and investors, regarding which we will inform the competent court and the public. In his attempt to bankrupt Immunotech Laboratories, Inc. (IMMB), Harry Zhabilov who was formerly the CEO, resigned from all positions on November, 2019 without informing the shareholders. In this way, he left the company without management, which he hid from all shareholders. Zhabilov also misappropriated the $190,000 wired by our company to IMMB for the validation batches, thus causing delay of the ITV-1 project. Zhabilov committed these actions in an attempt to illegally transfer all assets from Immunotech Laboratories Inc. to Enzolytics Inc., which has caused damages and lost profits to the shareholders of Immunotech Laboratories Inc. We will soon conduct a validation of the medicinal product ITV-1 with US Patent № 7,479,538 and the estimated release on the market is until 01/31/2022. In order to organize the production and bring ITV-1 to the market, Immunotech Laboratories BG signed a Joint Business Agreement with a strategic partner Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) through which the two companies are combining their efforts to realize the registration, production and distribution of medicinal products based on the Inactivated Pepsin Fraction (“IPF”) platform with U.S. Patents Nº 7,479,538, 7,625,565, 8,066,982, 8,067,531, 8,309,072.

For additional information you can contact us on the electronic mail immunotechlabsbg@gmail.com or visit the website www.immunh.com

Dimitar Savov
General Manager
Immunotech Laboratories BG

08/10/2021

TO THE SHAREHOLDERS OF IMMUNOTECH LABORATORIES INC. (IMMB)

Dear shareholders,
For more than 6 years, Harry Zhabilov, as the CEO of Immunotech Laboratories Inc. (IMMB), has not called for the mandatory yearly shareholder meeting and has been purposefully leading IMMB towards bankruptcy. For this reason, I, Dimitar Savov, as the owner of a control block in the company with 19.6% shares in IMMB and as the owner of 51% in Immunotech Laboratories BG, am initiating a yearly shareholder meeting of IMMB with the following agenda:

1. Change of the management of the company and the appointment of a new board of directors.
2. The start of a full revision of IMMB for the period 2012-2021.
3. To make the decision to seek responsibility from Harry Zhabilov for purposefully leading the company towards bankruptcy, an attempt to transfer company’s assets to ENZC, and a series of other criminal actions for his own benefit, which have caused serious harm to the company.
4. The adoption of a business plan for the period 2022-2027, which will be constructed and financed by Immunotech Laboratories BG. The expected investment equal around 11M US dollars.

Dear shareholders,
Please send us Your requests for participation in the shareholder meeting on our email immunotechlabsbg@gmail.com, so that we may select a specific date within the 12/10/21 and 12/20/21 period. You must provide Your current physical address within the request, at which we will send a written invitation, which contains all the necessary information conforming to IMMB’s bylaws. Under a good management, IMMB has a bright future on the basis of the developed by us medicinal products, but for that purpose we must unite our efforts and chose a good team, which can manage the company.
Please do not hesitate to ask us any questions regarding IMMB and Immunotech Laboratories BG via email. Let us unite our efforts so that we may protect our rights and our investment.

With respect,
Dimitar Savov
President of Immunotech Laboratories BG
Owner of control block in Immunotech Laboratories Inc.

14/06/2021

TO THE SHAREHOLDERS OF IMMUNOTECH LABORATORIES INC. (IMMB)

Dear shareholders in Immunotech Laboratories Inc. (IMMB),
For more than 5 years, the CEO of IMMB, Harry Zhabilov, has not organized the mandatory yearly shareholders meetings, has not made yearly balances of the company and has not conducted an audit of the company on purpose. I, Dimitar Savov, who own more than 15% in IMMB and am a majority shareholder in Immunotech Laboratories BG, believe that Zhabilov is purposefully leading IMMB towards bankruptcy in order to transfer its assets to a different company where he has more shares. All of us, the shareholders in IMMB, must unite and conduct a yearly shareholder meeting in order to elect a new board of directors. IMMB has an immense potential for profit and dividends, because the company owns 49% in Immunotech Laboratories BG; this means that IMMB will receive 49% of the profits from the sale of ITV-1, a medicinal product, which we have clinically tested for AIDS in Bulgaria (EU) and has shown very good treatment effect. Immunotech Laboratories BG has signed long-term agreements with many big partners for the sale of millions of sets of ITV-1 for countries like Ukraine, Greece, Romania, Turkey, and others. The average profit per set of ITV-1 will be 1500 EUR, which means profits in billions.
I ask for all shareholders in IMMB to contact us on immunotechlabsbg@gmail.com so we can coordinate our actions and bring IMMB to current status.

With respect,
Dimitar Savov
President of Immunotech Laboratories BG

20/12/2020

Current Information as of 12.20.2020

Immunotech Laboratories Inc. (IMMB) owns 49% of Immunotech Laboratories BG and I, Dimitar Savov, own the other 51%! Immunotech Laboratories BG owns the patent for the medicinal product ITV-1 - ImmunH and has successfully conducted a clinical trial on 31 patients in "Professor Ivan Kirov" Hospital, Sofia, Bulgaria, European Union.
We have tested ImmunH on patients who suffered from HIV/AIDS in a clinical trial conducted under the strict guidelines of the European Union. The results of the clinical trial have shown:
- improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8,
- decrease in the viral load,
- a good treatment effect on opportunistic infections,
- very good compatibility with all of the other modern antiretroviral drugs,
- very good tolerance in all patients and complete absence of side effects.
We are awaiting a permission for mass use.
We have begun the construction of a pharmaceutical factory on the territory of Bulgaria, for the purpose of which, Immunotech Laboratories BG has signed a contract to buy a nearly complete factory, which remains to be restructured to adhere to the guidelines for good manufacturing practice (GMP). The factory is estimated to be operational no later than 30.06.2021.
Dimitar Savov
President
Immunotech Laboratories BG

30/11/2020

WELCOME TO IMMUNOTECH LABORATORIES BG,

We are a corporation, which is dedicated to the development of medicine for HIV-1 Infection, Chronic Infection, Hepatitis(A,B,C), Rheumatoid Arthritis, some types of Cancer and viral diseases, which can be treated by an improvement in the immune system.

We have tested ImmunH on volunteers and the medicine has shown that it is highly effective(for full destruction of the viruses) and is absolutely harmless. ImmunH can also be used to strengthen the immune system in people that are not infected with a virus, because it is a natural product.

We have tested ImmunH on patients who suffered from HIV/AIDS in a clinical trial conducted under the strict guidelines of the European Union. The results of the clinical trial have shown:
improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8,
decrease in the viral load,
a good treatment effect on opportunistic infections,
very good compatibility with all of the other modern antiretroviral drugs,
very good tolerance in all patients and complete absence of side effects.

ImmunH is presented in the form of 16 injections, which are administrated biweekly on consecutive days for eight weeks using an intramuscular method. Before injection, the vial must be shaken and temperate to ambient temperature. One vial of the medicine contains 3 ml of the active compound per injection and must be stored in a surrounding with a temperature between +2°C to +8°C.

The medicine has a positive effect on the treatment of different kinds of cancer, as it stimulates the immune answer and strengthens the immune system of the human being.
"ImmunH" is the trade name of the medicine "ITV-1" .

Address

46 Tulch Str
Sofia
1000

Website

http://www.immunh.com/

Alerts

Be the first to know and let us send you an email when Immunotech Laboratories BG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Immunotech Laboratories BG:

Immunotech Laboratories BG